Kintor Pharmaceutical Announces Strategic Cooperation Agreement with Fonow Medicine for KT-939 Functional Cosmetics

Key Highlights

• Strategic Partnership: Kintor Pharmaceutical Limited (“Kintor”, Stock code: 9939) has entered into a strategic cooperation agreement with Zhejiang Fonow Medicine Co., Ltd (“Fonow Medicine”) for the joint development of whitening and freckle-removing functional cosmetics containing Kintor’s innovative raw material, KT-939.
• Focus on Melasma Treatment: The cosmetics to be developed will specifically target the reduction and improvement of skin pigmentation and will be used as adjuncts to Fonow’s core product, Folimei® Cream, a leading treatment for melasma in China.
• China Market Commercialization: Fonow Medicine is granted the right to develop, manufacture, and sell KT-939-based products in mainland China, leveraging its established network and expertise in topical dermatological drugs.
• Cashflow Utilization: Kintor plans to use cashflow generated from the KT-939 functional cosmetic raw material business to fund the development and commercialization of its core pipeline products, KX-826 and GT20029.
• Potential Shareholder Impact: This partnership is positioned to accelerate KT-939’s commercialization, broaden market coverage, and enhance Kintor’s financial flexibility, which could be significant for shareholders and potentially impact the share price.

Details of the Cooperation Agreement

On 12 March 2026, Suzhou Kintor Pharmaceuticals, Inc. (a wholly-owned subsidiary of Kintor) and Fonow Medicine signed a strategic cooperation agreement. Under the agreement:

• Kintor will supply the innovative cosmetic raw material KT-939 to Fonow Medicine.
• Fonow Medicine is authorized to develop, manufacture, and sell whitening and freckle-removing products using KT-939 as the main active ingredient, focusing on the mainland China market.
• These products are designed as adjuncts to Fonow’s flagship product, Folimei® Cream, which is widely used for melasma treatment.
• Both parties will collaborate on technology refinement and end-product development, advancing R&D, registration, and manufacturing of KT-939-based cosmetics, with Fonow Medicine leading commercialization efforts.

About Fonow Medicine

• Established in 2002, Fonow Medicine is a national high-tech enterprise specializing in the R&D, manufacture, and sales of topical dermatological drugs.
• Operates three R&D and manufacturing bases covering 180 acres, with GMP and ISO standard certifications.
• Developed significant dermatological products, including Fonow® Ointment (market leader in topical antibiotics for nine consecutive years) and Folimei® Cream (first-to-market generic for melasma in China, with both depigmenting and anti-irritation effects).

Strategic and Financial Implications

• The partnership is expected to accelerate the commercialization process for KT-939, broaden Kintor’s market reach, and translate technological advancements into market value.
• The cashflow from KT-939 sales will be crucial in funding Kintor’s core product pipeline, including KX-826 and GT20029, supporting the company’s sustainable growth strategy.
• The terms of the agreement are deemed fair and reasonable, on normal commercial terms, and in the best interests of the Company and its shareholders.
• Price Sensitivity: The potential for increased cashflow and accelerated product development could positively impact Kintor’s share value, especially if the KT-939 cosmetics gain strong market traction in China.

Management Statement

The Board, led by Chairman and CEO Dr. Youzhi Tong, views this cooperation as a key step toward sustainable development and steady growth. Investors are advised to exercise caution when dealing in the Company’s shares, considering pipeline development and commercialization risks, as well as the dependency on successful market adoption of KT-939-based products.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Shareholders and potential investors should conduct their own due diligence and consider risks associated with product development, regulatory approvals, and market acceptance before making investment decisions.

View KINTOR PHARMA-B Historical chart here